Howard W. Robin, President & CEO at NEKTAR THERAPEUTICS (NKTR), sold 11,232 shares at $45.16 ($528K) on 2025-09-09, disclosed to the SEC on 2025-09-11.
Scheduled sale ($528k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.16 | 2,100 | $95K | 18.0% |
| 2 | $46.41 | 1,200 | $56K | 10.6% |
| 3 | $46.41 | 1,200 | $56K | 10.6% |
| 4 | $47.49 | 2,156 | $102K | 19.4% |
| 5 | $47.49 | 2,156 | $102K | 19.4% |
| 6 | $48.18 | 1,210 |
| $58K |
| 11.0% |
| 7 | $48.18 | 1,210 | $58K | 11.0% |
| Total | $46.97 avg | 11,232 | $528K | 100% |
| Filing → |
| NKTR | SELL | 2026-05-21 | $29K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $31K | — | Filing → |
| NKTR | SELL | 2025-11-25 | $240K | — | Filing → |